Too often patients are blocked from receiving life-extending and life-saving medicines and treatments simply because healthcare systems are slow to accept and adopt transformational therapies. For example, research on CAR T-cell therapy shows that its benefits are not small advances but offer significant improvements and have curative potential for blood cancer patients; yet some patients are not able to access it. This fireside chat will examine the case study of CAR T-cell therapy and the importance of inspiring collective action from governments, payors, clinicians, and patients to strengthen pathways to innovative and transformational therapies. We cannot squander these critical investments in healthy aging and saving lives.
